These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 33484384)

  • 1. Topical cyclosporine a (0.05%) treatment in dry eye patients: a comparison study of Sjogren's syndrome versus non-Sjogren's syndrome.
    Cubuk MO; Ucgul AY; Ozgur A; Ozulken K; Yuksel E
    Int Ophthalmol; 2021 Apr; 41(4):1479-1485. PubMed ID: 33484384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Switching from Cyclosporine A 0.05% Anionic Emulsion to Cyclosporine A 0.1% Cationic Emulsion in Patients with Dry Eye Associated with Sjögren's Syndrome.
    Kim J; Moon TK; Yoon HJ; Ji YS; Yoon KC
    J Ocul Pharmacol Ther; 2021 Oct; 37(8):472-478. PubMed ID: 34449255
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of the Efficacy and Safety of Topical 0.05% Cyclosporine Eye Drops (II) in the Treatment of Dry Eye Associated with Primary Sjögren's Syndrome.
    Gao M; Zhao L; Liang R; Zhu Q; Zhao Q; Kong X
    Ocul Immunol Inflamm; 2023 Oct; 31(8):1662-1668. PubMed ID: 35914303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tear film microbiome in Sjogren's and non-Sjogren's aqueous deficiency dry eye.
    Pal S; Vani G; Donthineni PR; Basu S; Arunasri K
    Indian J Ophthalmol; 2023 Apr; 71(4):1566-1573. PubMed ID: 37026303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of intense pulsed light combined with topical 0.05% Cyclosporin A eyedrops in the treatment of Sjögren's syndrome related dry eye.
    Huo Y; Huang X; Lin L; Yang S; Qin Z; Yirui Z; Mou Y; Jin X
    Expert Rev Clin Immunol; 2024 Oct; 20(10):1261-1267. PubMed ID: 38785065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tear Osmolarity and Matrix Metallopeptidase-9 in Dry Eye Associated with Sjögren's Syndrome.
    Kook KY; Jin R; Li L; Yoon HJ; Yoon KC
    Korean J Ophthalmol; 2020 Jun; 34(3):179-186. PubMed ID: 32495525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Manifestation of meibomian gland dysfunction in patients with Sjögren's syndrome, non-Sjögren's dry eye, and non-dry eye controls.
    Kang YS; Lee HS; Li Y; Choi W; Yoon KC
    Int Ophthalmol; 2018 Jun; 38(3):1161-1167. PubMed ID: 28567496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sjögren's Syndrome, Non-Sjögren's Syndrome, and Graft-Versus-Host Disease Related Dry Eye.
    Ogawa Y
    Invest Ophthalmol Vis Sci; 2018 Nov; 59(14):DES71-DES79. PubMed ID: 30481809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of topical 0.05 % cyclosporine A in patients with dry eye disease associated with Sjögren's syndrome.
    Devecı H; Kobak S
    Int Ophthalmol; 2014 Oct; 34(5):1043-8. PubMed ID: 24442759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is Sjögren's syndrome dry eye similar to dry eye caused by other etiologies? Discriminating different diseases by dry eye tests.
    Garcia DM; Reis de Oliveira F; Módulo CM; Faustino J; Barbosa AP; Alves M; Rocha EM
    PLoS One; 2018; 13(12):e0208420. PubMed ID: 30507949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A 0,05% cyclosporine treatment of the advanced dry eye syndrome].
    Kujawa A; Rózycki R
    Klin Oczna; 2005; 107(4-6):280-6. PubMed ID: 16118939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the first tear film break-up point in Sjögren's syndrome and non-Sjögren's syndrome dry eye patients.
    Zhao S; Le Q
    BMC Ophthalmol; 2022 Jan; 22(1):1. PubMed ID: 34980014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the effect of topical tacrolimus 0.03% versus cyclosporine 0.05% in the treatment of dry eye secondary to Sjogren syndrome.
    Moawad P; Shamma R; Hassanein D; Ragab G; El Zawahry O
    Eur J Ophthalmol; 2022 Jan; 32(1):673-679. PubMed ID: 33530719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of Sjögren's versus non-Sjögren's related dry eye in a longitudinal, tertiary clinic-based sample.
    Cui D; Mathews P; Li G; VanCourt S; Akpek E
    PLoS One; 2021; 16(12):e0261241. PubMed ID: 34919587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dry eye in Sjögren's syndrome - characteristics and therapy.
    Caban M; Omulecki W; Latecka-Krajewska B
    Eur J Ophthalmol; 2022 Nov; 32(6):3174-3184. PubMed ID: 35354331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Efficacy of Diquafosol Ophthalmic Solution in Non-Sjögren and Sjögren Syndrome Dry Eye Patients Unresponsive to Artificial Tear.
    Jeon HS; Hyon JY
    J Ocul Pharmacol Ther; 2016 Sep; 32(7):463-8. PubMed ID: 27294831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Sjögren's syndrome dry eye using 0.03% tacrolimus eye drop: Prospective double-blind randomized study.
    Moscovici BK; Holzchuh R; Sakassegawa-Naves FE; Hoshino-Ruiz DR; Albers MB; Santo RM; Hida RY
    Cont Lens Anterior Eye; 2015 Oct; 38(5):373-8. PubMed ID: 25956572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does Sjogren's syndrome affect only the lacrimal gland in the eye? Time to replace the missing stones.
    Gurlevik U; Karakoyun A; Yasar E
    Indian J Ophthalmol; 2021 Jan; 69(1):53-57. PubMed ID: 33323573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corneal nerve structure in patients with primary Sjögren's syndrome in China.
    Li F; Zhang Q; Ying X; He J; Jin Y; Xu H; Cheng Y; Zhao M
    BMC Ophthalmol; 2021 May; 21(1):211. PubMed ID: 33980205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cohort study of T helper 17 cell-related cytokine levels in tear samples of systemic lupus erythematosus and Sjögren's syndrome patients with dry eye disease.
    Peng X; Lu Y; Wei J; Lin T; Lu Q; Liu Q; Ting WJ
    Clin Exp Rheumatol; 2021; 39 Suppl 133(6):159-165. PubMed ID: 34596026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.